Danco Laboratories

The U.S. Supreme Court allowed telehealth access to mifepristone to continue until the 5th Circuit Court rules on Louisiana's lawsuit challenging the FDA's telehealth access rule. Justices Samuel Alito and Clarence Thomas dissented, citing the Comstock Act and manufacturer losses. The decision brings relief to abortion rights advocates but faces criticism from opponents.

The U.S. Supreme Court allowed telehealth access to abortion medication mifepristone to continue under current FDA rules while the U.S. 5th Circuit Court of Appeals decides the case Louisiana v. Food and Drug Administration. Justices Samuel Alito and Clarence Thomas dissented, with Thomas citing the Comstock Act as a legal basis to challenge the FDA's rule. Abortion-rights advocates welcomed the decision, while opponents criticized it as endangering patients.

The U.S. Supreme Court ruled that telehealth access to abortion medication mifepristone can continue under current FDA rules until the 5th Circuit Court of Appeals decides the case Louisiana v. Food and Drug Administration. Justices Samuel Alito and Clarence Thomas dissented, citing the Comstock Act and concerns about irreparable harm. The decision follows a 10-day stay issued after Louisiana officials challenged the FDA's telehealth access rule.

The Supreme Court has indefinitely extended a freeze on strict new restrictions for dispensing the abortion pill mifepristone, providing legal certainty for pharmacies and clinicians. The order allows teleprescribing and mailing of abortion drugs to continue. The case will likely end up at the Supreme Court again soon.

The Supreme Court has allowed the mail-order distribution of the abortion pill mifepristone pending appeal. This decision comes after two drugmakers, Danco Laboratories and GenBioPro, asked the court to lift an appeals court ban. The move will enable women to access the medication via mail

The Supreme Court preserved women's access to the abortion pill mifepristone, rejecting lower-court restrictions while a lawsuit continues. The court's order allows women to continue obtaining the drug at pharmacies or through the mail without an in-person visit to a doctor. Access is likely to remain uninterrupted until next year as the case plays out.

The Supreme Court extended a freeze on new restrictions for dispensing the abortion pill mifepristone, allowing continued mail-order prescribing. The extension provides a reprieve for pharmacies and telehealth companies. The freeze will run through Thursday at 5 p.m.

Two drugmakers, Danco Laboratories and GenBioPro, have asked the US Supreme Court to restore mail-order access to the abortion pill mifepristone, while UCB has acquired Candid Therapeutics in a deal worth $2.2 billion to expand its presence in autoimmune disease therapies.

A drugmaker of mifepristone, a key abortion pill, filed an emergency appeal with the U.S. Supreme Court to restore access for Americans who receive the medication by mail. The request follows recent restrictions limiting mail delivery of the pill.

The Supreme Court faces an emergency request from Danco Laboratories, the manufacturer of mifepristone, to block a 5th Circuit Court ruling that restricts mail-order access to the abortion pill. The ruling has caused legal and logistical uncertainty, prompting warnings of 'chaos' in medical settings and debates over FDA regulations.

The Supreme Court is considering an emergency request from Danco Laboratories, the manufacturer of mifepristone, to block a 5th Circuit Court ruling that restricts mail-order access to the abortion pill and reinstates in-person requirements. Danco claims the ruling is causing 'chaos' and uncertainty in medical settings, disrupting patient access and creating legal ambiguity.

The Supreme Court has been asked to pause a ruling that restricts telehealth and mail access to abortion pills. Danco Laboratories, the manufacturer of mifepristone, argues the lower court's decision to immediately limit the drug's sale to in-person distribution was excessive.

Sen. Josh Hawley urges the DOJ to investigate Danco Laboratories over safety concerns regarding mifepristone, an abortion drug linked to serious adverse events. Hawley highlights the company's secretive structure and alleges it prioritizes profits over patient safety, citing a study showing 10.93% of users experienced severe complications.